<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="407">
  <stage>Registered</stage>
  <submitdate>6/09/2005</submitdate>
  <approvaldate>7/09/2005</approvaldate>
  <actrnumber>ACTRN12605000330640</actrnumber>
  <trial_identification>
    <studytitle>Open Uncontrolled Cohort Study to Assess the Impact of Sibutramine-Assisted Weight Loss in Sleep Apnea in Men</studytitle>
    <scientifictitle>Open Uncontrolled Cohort Study to Assess the Impact of Sibutramine-Assisted Weight Loss in Sleep Apnea in Men</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Obstructive Sleep Apnea and Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Sleep apnoea</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Sibutramine Assisted Weight Loss Programme. Sibutrmaine(Reductil)10-15 mg plus an exercise progrmamme and an dietary intervention for 6 months.</interventions>
    <comparator />
    <control>Active</control>
    <interventioncode>None</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Effect on the severity of Obstructive Sleep Apnea over a 6 month period.</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Effect on cardiovascular and metabolic markers (eg cholesterol, glucoese, insulin etc).</outcome>
      <timepoint>After 6 months.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Moderate to Severe Obstructive Sleep Apnea male subjects with obesity (Body Mass Index 30-38 kg/m2).</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>Not stated</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Signficant cardiovascular, respiratroy, metabolic ,renal, gastrointestinal or psychiatric disorder. Recent use of Continuous Positive Airway Pressure (CPAP) or upper airway surgery.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Open (masking not used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2002</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>100</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>NHMRC</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>NHMRC</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Commercial sector/Industry</sponsortype>
      <sponsorname>Abbott Pharmaceuticals</sponsorname>
      <sponsoraddress />
      <sponsorcountry>United States of America</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Royal Prince Alfred Hospital</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Brendon Yee</name>
      <address>Sleep Unit
Department of Respiratory and Sleep Medicine
Royal Prince Alfred Hospital
Camperdown NSW 2050</address>
      <phone>+61 2 95158190</phone>
      <fax>+61 2 95157196</fax>
      <email>brendony@med.usyd.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Wendy Taylor</name>
      <address>PO Box M77
Missenden Road
Camperdown NSW 2050</address>
      <phone>+61 2 95156578</phone>
      <fax>+61 2 95505865</fax>
      <email>wtaylor@woolcock.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>